Skip to content

Study on the Pathogenesis of Psoriasis and the Therapeutic Mechanisms of Uighur Medicine

Study on the Pathogenesis of Psoriasis and the Therapeutic Mechanisms of Uighur Medicine

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000320
Enrollment
Unknown
Registered
2024-08-28
Start date
2023-12-15
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Sponsors

Xinjiang Uyghur Autonomous Region Uyghur Medical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Patients with mild to moderate plaque psoriasis according to Western medical diagnostic criteria. (2)PASI score < 10 BSA < 10% DLQI < 10. (3)Patients with plaque psoriasis that according to Uighur medicine differentiation analysis meet the diagnosis of salty and mucous constitution. (4)Age between 18 and 65 years. (5)Informed consent and voluntary participation.

Exclusion criteria

Exclusion criteria: (1)Reverse psoriasis and mucosal psoriasis. (2)Patients with tuberculosis or cancer. (3)Patients with severe heart failure or severe primary diseases of the liver or kidneys (Note: ALT AST exceeding twice the upper limit of normal range; Cr exceeding the upper limit of normal range). (4)Use of corticosteroids or any psoriasis treatment medication within the past 2 weeks; and/or use of retinoids or topical corticosteroids or any topical psoriasis treatment medication within the past week. (5)Women planning to become pregnant currently pregnant or breastfeeding. (6)Suspected or confirmed history of alcohol or drug abuse. (7)Allergic individuals (allergic to more than 2 other drugs) or those allergic to any components of the medications in this study. (8)Other conditions that may reduce the likelihood of participation or complicate enrollment such as frequent changes in work environment mental disorders communication difficulties etc. as deemed inappropriate for participation by the investigator. (9)Participation in other drug clinical studies within the past month or currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
psoriasis area and severity index (PASI);

Secondary

MeasureTime frame
Post-drug efficacy;Uighur Medicine Clinical Syndrome Score;Length of hospital stay;BSA Score;

Countries

China

Contacts

Public ContactLi Zhi jian

Xinjiang Uyghur Autonomous Region Uyghur Medical Hospita Affiliation

lizhijian0220@sina.com15981799975

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026